Daily Stock Analysis, AZN, AstraZeneca PLC, priceseries

AstraZeneca PLC. Daily Stock Analysis
Stock Information
Open
38.97
Close
39.98
High
40.15
Low
38.89
Previous Close
36.58
Daily Price Gain
3.40
YTD High
40.15
YTD High Date
Feb 14, 2019
YTD Low
35.30
YTD Low Date
Jan 28, 2019
YTD Price Change
2.18
YTD Gain
5.77%
52 Week High
41.77
52 Week High Date
Nov 13, 2018
52 Week Low
32.32
52 Week Low Date
Mar 1, 2018
52 Week Price Change
6.34
52 Week Gain
18.85%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 3. 2017
25.63
Mar 7. 2017
27.67
21 Trading Days
7.95%
Link
LONG
May 9. 2017
29.29
Jun 9. 2017
32.63
22 Trading Days
11.43%
Link
LONG
Aug 31. 2017
28.69
Oct 23. 2017
33.08
36 Trading Days
15.29%
Link
Company Information
Stock Symbol
AZN
Exchange
NYSE
Company URL
http://www.astrazeneca.com
Company Phone
011 44 20 7304 5000
CEO
Pascal Soriot
Headquarters
-
Business Address
1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE, UNITED KINGDOM CB2 0AA
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0000901832
About

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. It operates through the following geographical segments: UK; Continental Europe; The Americas; Asia, Africa & Australasia. It produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. It distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. The company was founded on April 6, 1999 and is headquartered in London, the United Kingdom.

Description

AstraZeneca PLC engages in the discovery, development, manufacture, and commercialization of prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. Its marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. It serves primary care and specialty care physicians through distributors and local representative offices. The company's pipeline includes 132 projects, of which 120 are in the clinical phase of development. It has collaboration agreements with Valeant Holdings Ireland, and Eli Lilly and Company; definitive agreement with Foundation Medicine, Inc.; strategic collaboration with FibroGen and Astellas; collaboration and license agreement with Celgene International Sarl; and license agreement with LEO Pharma A/S. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.